CRISPR市場：製品別（酵素、キット、ライブラリ）、サービス別（gRNA設計、細胞株工学、スクリーニング）、用途別（創薬・開発、農業）、エンドユーザー別（製薬、バイオテクノロジー、CRO、研究機関） - 2028年までの世界予測

CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028

CRISPR市場は、予測期間中に15.6%のCAGRで、2023年の34億米ドルから2028年には71億米ドルに達すると予測されている。CRISPR市場の成長を促進する主な要因は、遺伝子編集技術の進歩と需要の増加であり、政府や民間... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年6月30日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	200	248	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

CRISPR市場は、予測期間中に15.6%のCAGRで、2023年の34億米ドルから2028年には71億米ドルに達すると予測されている。CRISPR市場の成長を促進する主な要因は、遺伝子編集技術の進歩と需要の増加であり、政府や民間組織の資金調達と投資の増加が市場の成長を促進すると予想される。しかし、倫理的・規制的な考慮が市場の成長をある程度抑制すると予想される。
CRISPR市場は、製品、用途、エンドユーザー、地域によって区分されている。
"製品・サービス別では、製品分野がCRISPR市場で最大シェアを占める"
製品・サービスに基づき、CRISPR市場は製品、サービスに分類される。遺伝子編集技術領域におけるCRISPR製品に対する需要の高まりにより、製品セグメントが2023年の市場を支配した。これとともに、送達システムの進歩、遺伝子編集研究への投資の増加、学術機関と製薬企業との共同研究の増加などが、CRISPR市場における製品の成長率上昇につながっている。
"用途別では、創薬・開発分野がCRISPR市場で最大のシェアを占める"
用途別に見ると、CRISPR市場は創薬・開発、農業、その他の用途に区分される。2023年には、創薬・開発分野がCRISPR市場でより大きなシェアを占めた。この市場セグメントの成長は、遺伝子の編集と操作においてCRISPR-Cas9が提供する卓越した精度と効率に起因している。これとともに、個別化医療に対する需要の高まりや、CRISPR技術の分野における研究開発活動の活発化が、創薬・開発分野でのCRISPRの採用に寄与している。

"北米：CRISPR市場の最大シェア"
CRISPR市場で最大のシェアを占めたのは北米である。北米地域の大きなシェアは、高度なインフラ、最先端の研究機関、遺伝子編集研究に特化したバイオテクノロジー企業やCROの強力なエコシステムなど、同地域で確立されたヘルスケアおよびバイオテクノロジー産業に起因している。北米には、遺伝子編集研究に特化したプログラムや専門知識を有する一流の学術機関や民間企業が存在し、CRISPR市場の成長に寄与している。
「アジア太平洋：CRISPR市場で最も急成長している地域"
アジア太平洋地域のCRISPR市場は、予測期間中に最も高いCAGRで成長すると予測されている。この背景には、個別化医療の需要増加、シーケンス技術の進歩がある。アジア太平洋CRISPR市場のもう1つの主要な促進要因は、この地域の人口の多さと急増である。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 役職別エグゼクティブ：55％、リサーチ・サイエンティスト：25％、マネージャー：20
- 国別北米50％、欧州20％、アジア太平洋地域15％、中南米10％、中東アフリカ5

著名プレイヤー
- サーモフィッシャーサイエンティフィック社（米国）
- メルクKGaA（ドイツ）
- アジレント・テクノロジー（米国）
- ジェンスクリプト・バイオテック・コーポレーション（中国）
- CRISPR Therapeutics AG（スイス）
- エディタス・メディシン（米国）
- インテリア・セラピューティクス社（米国）
- ビーム・セラピューティクス（米国）
- カリブー・バイオサイエンシズ（米国）
- ロンザグループ（スイス(スイス）
- ダナハー社（米国）
- パーキンエルマー社（米国）
- ヘラバイオラボ（米）
- オリジーン・テクノロジーズ（米）
- セレクタ（米）
- マンモス・バイオサイエンシズ（米）
- アプライド・ステムセル（米）
- ニューイングランドバイオラボ社（米国）
- ツールジェン社（韓国）
- ジーンコピア社（米国）
- ツイストバイオサイエンス（米）
- シンセゴ・コーポレーション（米国）
- イージェネシス（米）
- インスクリプタ社（米国）
- プレシジョン・バイオサイエンシズ（米）
調査範囲
この調査レポートは、CRISPR市場の詳細な姿を提供しています。製品＆サービス（製品（CRISPRキット＆酵素、CRISPRライブラリ、その他製品）、サービス（gRNA合成＆細胞株開発、CRISPRスクリーニング＆バリデーションサービス、その他サービス））、用途（創薬＆開発、農業、その他用途）、エンドユーザー（製薬・バイオテクノロジー企業、学術・研究機関、その他用途）、地域（北米、欧州、アジア太平洋、中南米、中東アフリカ）など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主なメリット
本レポートは、CRISPR市場全体とそのセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、動向、機会、および課題に関する情報を提供することを可能にする。
本レポートは、以下のポイントに関する洞察を提供します：
- CRISPR市場の成長に影響を与える主な促進要因（CRISPRベースの遺伝子治療に対する需要の増加、CRISPR技術の進歩と採用の増加、CRISPR技術に対する政府からの投資と資金の増加）、阻害要因（CRISPR技術に関連する技術的課題）、機会（新しいワクチンの開発と遺伝性疾患の治療）、課題（CRISPRの進歩に対する規制上のハードル）の分析。
- 製品開発/イノベーション：CRISPR市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報-本レポートは様々な地域のCRISPR市場を分析しています。
- 市場の多様化：CRISPR市場における新製品、未開拓の地域、最近の開発、投資に関する詳細な情報。
- 競合評価：CRISPR市場戦略におけるThermo Fisher Scientific, Inc.（米国）、Merck KGaA（ドイツ）、Agilent Technologies, Inc.（米国）、Genscript Biotech Corporation（中国）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。また、本レポートは、利害関係者が遺伝子編集市場の脈動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供する。

ページTOPに戻る

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 33
FIGURE 2 BREAKDOWN OF PRIMARIES: CRISPR MARKET 34
2.2 MARKET ESTIMATION METHODOLOGY 34
FIGURE 3 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 34
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 35
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 36
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 36
2.3 MARKET GROWTH RATE PROJECTIONS 37
FIGURE 6 CRISPR MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 37
FIGURE 7 CRISPR MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 38
2.3.1 DATA TRIANGULATION 38
FIGURE 8 DATA TRIANGULATION METHODOLOGY 39
2.4 RESEARCH ASSUMPTIONS 39
2.5 RISK ANALYSIS 40
2.6 RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 40
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 40

3 EXECUTIVE SUMMARY 42
FIGURE 9 CRISPR MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 42
FIGURE 10 CRISPR MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT 44
4 PREMIUM INSIGHTS 45
4.1 CRISPR MARKET OVERVIEW 45
FIGURE 12 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 45
4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2023) 46
FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 46
4.3 CRISPR MARKET SHARE, BY END USER, 2023 VS. 2028 46
FIGURE 14 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 15 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
TABLE 4 CRISPR MARKET: IMPACT ANALYSIS 48
5.2.1 DRIVERS 48
5.2.1.1 Growing demand for CRISPR-based gene therapies 48
5.2.1.2 Advancements in CRISPR technology 49
5.2.1.3 Growing government and private investments and funding for CRISPR technology 49
TABLE 5 RECENT INVESTMENTS IN CRISPR (JANUARY 2020 TO JUNE 2023) 50
5.2.2 RESTRAINTS 50
5.2.2.1 Technical challenges associated with CRISPR technology 50
5.2.3 OPPORTUNITIES 51
5.2.3.1 Development of new vaccines and treatments for genetic diseases 51
5.2.4 CHALLENGES 51
5.2.4.1 Regulatory hurdles for CRISPR advancements 51
5.3 TECHNOLOGY ANALYSIS 52
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
FIGURE 16 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
5.5 SUPPLY AND VALUE CHAIN ANALYSIS 55
5.5.1 CRISPR MARKET: SUPPLY CHAIN ANALYSIS 55
FIGURE 17 CRISPR MARKET: SUPPLY CHAIN ANALYSIS 55
5.5.2 CRISPR MARKET: VALUE CHAIN ANALYSIS 56
FIGURE 18 CRISPR MARKET: VALUE CHAIN ANALYSIS 56

5.6 ECOSYSTEM ANALYSIS 57
FIGURE 19 CRISPR MARKET: ECOSYSTEM ANALYSIS 57
5.7 PORTER’S FIVE FORCES ANALYSIS 57
TABLE 6 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 57
5.7.1 THREAT OF NEW ENTRANTS 57
5.7.2 THREAT OF SUBSTITUTES 58
5.7.3 BARGAINING POWER OF BUYERS 58
5.7.4 BARGAINING POWER OF SUPPLIERS 58
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.8 REGULATORY ANALYSIS 59
5.8.1 FDA APPROVALS 60
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
5.9 PRICING ANALYSIS 64
TABLE 12 AVERAGE SELLING PRICES OF PRODUCTS OFFERED BY KEY PLAYERS 64
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS 64
5.10 PATENT ANALYSIS 65
FIGURE 20 PATENTS GRANTED FOR CRISPR TECHNOLOGY, JANUARY 2016 TO JUNE 2023 65
TABLE 13 TOP OWNERS OF CRISPR PATENTS 65
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 66
TABLE 14 CRISPR CONFERENCES (2023–2024) 66
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 21 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 66
5.12.2 CRISPR MARKET: BUYING CRITERIA 67
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 67
6 CRISPR MARKET, BY PRODUCT & SERVICE 68
6.1 INTRODUCTION 69
TABLE 15 CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 69
6.2 PRODUCTS 69
TABLE 16 CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 70
TABLE 17 CRISPR PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 70
TABLE 18 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 70
TABLE 19 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 20 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 21 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
6.2.1 CRISPR ENZYMES AND KITS 72
6.2.1.1 CRISPR enzymes and kits segment dominated CRISPR products market 72
TABLE 22 CRISPR ENZYMES AND KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 72
TABLE 23 NORTH AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 24 EUROPE: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 25 ASIA PACIFIC: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 26 LATIN AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.2.2 CRISPR LIBRARIES 74
6.2.2.1 Increasing applications of CRISPR libraries in gene editing to drive growth 74
TABLE 27 CRISPR LIBRARIES MARKET, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 28 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 29 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 30 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 31 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.3 OTHER PRODUCTS 76
TABLE 32 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 33 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 34 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 35 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 36 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
6.3 SERVICES 78
TABLE 37 CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 79
TABLE 38 CRISPR SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 39 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 40 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 41 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 42 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.3.1 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT 81
6.3.1.1 Emerging opportunities in CRISPR gRNA synthesis and cell line development to drive growth 81
TABLE 43 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 44 NORTH AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 45 EUROPE: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 46 ASIA PACIFIC: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 47 LATIN AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.3.2 SCREENING AND VALIDATION 83
6.3.2.1 Rapid advancements in CRISPR technology to drive growth 83
TABLE 48 CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 49 NORTH AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 50 EUROPE: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 51 ASIA PACIFIC: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 52 LATIN AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3.3 OTHER SERVICES 85
TABLE 53 OTHER CRISPR SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 54 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 55 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 56 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 57 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
7 CRISPR MARKET, BY APPLICATION 87
7.1 INTRODUCTION 88
TABLE 58 CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
7.2 DRUG DISCOVERY AND DEVELOPMENT 88
7.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 88
TABLE 59 CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 60 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 61 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 62 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 63 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.3 AGRICULTURE 91
7.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH 91
TABLE 64 CRISPR MARKET FOR AGRICULTURE, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 65 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 66 EUROPE: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 67 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 68 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
7.4 OTHER APPLICATIONS 93
TABLE 69 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 70 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 71 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 72 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 73 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
8 CRISPR MARKET, BY END USER 95
8.1 INTRODUCTION 96
TABLE 74 CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 96
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 96
8.2.1 GROWING DEMAND FOR CRISPR-BASED THERAPIES TO PROPEL GROWTH 96
TABLE 75 CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 76 NORTH AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 77 EUROPE: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 78 ASIA PACIFIC: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 79 LATIN AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
8.3 ACADEMIC AND RESEARCH INSTITUTES 98
8.3.1 GROWING FOCUS ON DEVELOPING INNOVATIVE THERAPIES TO DRIVE GROWTH 98
TABLE 80 CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 81 NORTH AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 82 EUROPE: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 83 ASIA PACIFIC: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 84 LATIN AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
8.4 OTHER END USERS 101
TABLE 85 CRISPR MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 86 NORTH AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 87 EUROPE: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 88 ASIA PACIFIC: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 89 LATIN AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
9 CRISPR MARKET, BY REGION 103
9.1 INTRODUCTION 104
TABLE 90 CRISPR MARKET, BY REGION, 2021–2028 (USD MILLION) 104
9.2 NORTH AMERICA 104
FIGURE 23 NORTH AMERICA: CRISPR MARKET SNAPSHOT 105
TABLE 91 NORTH AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 106
TABLE 92 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 93 NORTH AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 94 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 95 NORTH AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.2.1 US 107
9.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth 107
TABLE 96 US: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108
TABLE 97 US: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 98 US: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 99 US: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
TABLE 100 US: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2.2 CANADA 109
9.2.2.1 Increasing demand for gene-editing technologies to boost growth 109
TABLE 101 CANADA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 110
TABLE 102 CANADA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 103 CANADA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 104 CANADA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 105 CANADA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.2.3 NORTH AMERICA: IMPACT OF RECESSION 111
9.3 EUROPE 111
TABLE 106 EUROPE: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 107 EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 112
TABLE 108 EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 109 EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 110 EUROPE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 111 EUROPE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 114
9.3.1 GERMANY 114
9.3.1.1 Rapidly increasing biotechnology sector to support growth 114
TABLE 112 GERMANY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 114
TABLE 113 GERMANY: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 114 GERMANY: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 115 GERMANY: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 116 GERMANY: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.3.2 UK 116
9.3.2.1 Significant government investments in genomics research to propel growth 116
TABLE 117 UK: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
TABLE 118 UK: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 119 UK: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 120 UK: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 121 UK: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.3.3 FRANCE 118
9.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth 118
TABLE 122 FRANCE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 123 FRANCE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 124 FRANCE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 125 FRANCE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 126 FRANCE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.4 ITALY 120
9.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth 120
TABLE 127 ITALY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 121
TABLE 128 ITALY: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 129 ITALY: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 130 ITALY: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 131 ITALY: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.3.5 SPAIN 122
9.3.5.1 Increasing demand for precision medicine to drive growth 122
TABLE 132 SPAIN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123
TABLE 133 SPAIN: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 134 SPAIN: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 135 SPAIN: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 136 SPAIN: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.3.6 REST OF EUROPE 124
TABLE 137 REST OF EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 138 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 139 REST OF EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 140 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 141 REST OF EUROPE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.3.7 EUROPE: IMPACT OF RECESSION 126
9.4 ASIA PACIFIC 127
FIGURE 24 ASIA PACIFIC: CRISPR MARKET SNAPSHOT 127
TABLE 142 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 143 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 144 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 145 ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 146 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 147 ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.4.1 CHINA 130
9.4.1.1 Increasing investments in R&D to drive growth 130
TABLE 148 CHINA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130
TABLE 149 CHINA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 150 CHINA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 151 CHINA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 152 CHINA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.4.2 JAPAN 132
9.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth 132
TABLE 153 JAPAN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 132
TABLE 154 JAPAN: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 155 JAPAN: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 156 JAPAN: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 157 JAPAN: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 134
9.4.3 INDIA 134
9.4.3.1 Increasing prevalence of genetic disorders to support growth 134
TABLE 158 INDIA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 159 INDIA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 160 INDIA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 161 INDIA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 162 INDIA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 135
9.4.4 REST OF ASIA PACIFIC 136
TABLE 163 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
TABLE 164 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 165 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 166 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 167 REST OF ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 137
9.4.5 ASIA PACIFIC: IMPACT OF RECESSION 137
9.5 LATIN AMERICA 138
TABLE 168 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 169 LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 170 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 171 LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 172 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 173 LATIN AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 140
9.5.1 BRAZIL 140
9.5.1.1 Growing adoption of genome technologies to propel growth 140
TABLE 174 BRAZIL: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 141
TABLE 175 BRAZIL: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 176 BRAZIL: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 177 BRAZIL: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 178 BRAZIL: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 142
9.5.2 REST OF LATIN AMERICA 142
TABLE 179 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 180 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 181 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 182 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 183 REST OF LATIN AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 144
9.5.3 LATIN AMERICA: IMPACT OF RECESSION 144
9.6 MIDDLE EAST & AFRICA 145
TABLE 184 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 185 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 186 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 187 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 188 MIDDLE EAST & AFRICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 146
9.6.1 MIDDLE EAST & AFRICA: IMPACT OF RECESSION 147
10 COMPETITIVE LANDSCAPE 148
10.1 INTRODUCTION 148
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 148
FIGURE 25 CRISPR MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 149
10.3 REVENUE SHARE ANALYSIS (TOP 4 PLAYERS) 149
FIGURE 26 REVENUE ANALYSIS FOR TOP 4 COMPANIES (2020−2022) 149
10.4 MARKET SHARE ANALYSIS (2022) 150
FIGURE 27 CRISPR MARKET: MARKET SHARE ANALYSIS (2022) 150
10.5 COMPANY EVALUATION MATRIX 151
FIGURE 28 CRISPR MARKET: COMPANY EVALUATION MATRIX (2022) 152
10.5.1 STARS 153
10.5.2 EMERGING LEADERS 153
10.5.3 PERVASIVE PLAYERS 153
10.5.4 PARTICIPANTS 153
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES (2022) 153
10.6.1 PROGRESSIVE COMPANIES 153
10.6.2 STARTING BLOCKS 153
10.6.3 RESPONSIVE COMPANIES 154
10.6.4 DYNAMIC COMPANIES 154
FIGURE 29 CRISPR MARKET: START-UP/SME EVALUATION MATRIX (2022) 154
10.7 COMPETITIVE BENCHMARKING 155
10.7.1 LIST OF START-UP/SME PLAYERS 155
TABLE 189 CRISPR MARKET: LIST OF START-UP/SME PLAYERS 155
10.7.2 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 156
TABLE 190 CRISPR MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 156
10.8 COMPETITIVE SCENARIO AND TRENDS 157
TABLE 191 CRISPR MARKET: DEALS 157
10.8.1 PRODUCT LAUNCHES 158
TABLE 192 CRISPR MARKET: PRODUCT LAUNCHES 158
10.8.2 OTHER DEVELOPMENTS 158
TABLE 193 CRISPR MARKET: OTHER DEVELOPMENTS 158
11 COMPANY PROFILES 159
11.1 KEY PLAYERS 159
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 THERMO FISHER SCIENTIFIC INC. 159
TABLE 194 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 159
11.1.2 MERCK KGAA 163
TABLE 195 MERCK KGAA: COMPANY OVERVIEW 163
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2022) 164
11.1.3 AGILENT TECHNOLOGIES, INC. 167
TABLE 196 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 167
FIGURE 32 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022) 168
11.1.4 GENSCRIPT 171
TABLE 197 GENSCRIPT: COMPANY OVERVIEW 171
FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2022) 172
11.1.5 CRISPR THERAPEUTICS AG 175
TABLE 198 CRISPR THERAPEUTICS AG: COMPANY OVERVIEW 175
FIGURE 34 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022) 175
11.1.6 EDITAS MEDICINE 177
TABLE 199 EDITAS MEDICINE: COMPANY OVERVIEW 177
FIGURE 35 EDITAS MEDICINE: COMPANY SNAPSHOT (2022) 177
11.1.7 INTELLIA THERAPEUTICS INC. 179
TABLE 200 INTELLIA THERAPEUTICS INC.: COMPANY OVERVIEW 179
FIGURE 36 INTELLIA THERAPEUTICS INC.: COMPANY SNAPSHOT (2022) 179
11.1.8 BEAM THERAPEUTICS, INC. 181
TABLE 201 BEAM THERAPEUTICS INC.: COMPANY OVERVIEW 181
FIGURE 37 BEAM THERAPEUTICS INC.: COMPANY SNAPSHOT (2022) 181
11.1.9 CARIBOU BIOSCIENCES 183
TABLE 202 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW 183
11.1.10 LONZA GROUP LTD. 184
TABLE 203 LONZA: COMPANY OVERVIEW 184
FIGURE 38 LONZA: COMPANY SNAPSHOT (2022) 185
11.1.11 DANAHER CORPORATION 187
TABLE 204 DANAHER CORPORATION: COMPANY OVERVIEW 187
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 188
11.1.12 PERKINELMER (REVVITY, INC.) 189
TABLE 205 PERKINELMER: COMPANY OVERVIEW 189
FIGURE 40 PERKINELMER: COMPANY SNAPSHOT (2022) 190
11.1.13 HERA BIOLABS 192
TABLE 206 HERA BIOLABS: COMPANY OVERVIEW 192
11.1.14 ORIGENE TECHNOLOGIES, INC. 193
TABLE 207 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 193
11.1.15 CELLECTA, INC. 194
TABLE 208 CELLECTA, INC.: COMPANY OVERVIEW 194
11.2 OTHER PLAYERS 196
11.2.1 MAMMOTH BIOSCIENCES INC. 196
11.2.2 APPLIED STEMCELL 196
11.2.3 NEW ENGLAND BIOLABS INC. 197
11.2.4 TOOLGEN INC. 197
11.2.5 GENECOPOEIA, INC. 198
11.2.6 TWIST BIOSCIENCE CORP. 198
11.2.7 SYNTHEGO CORPORATION 199
11.2.8 EGENESIS 199
11.2.9 INSCRIPTA, INC. 200
11.2.10 PRECISION BIOSCIENCES, INC. 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX 201
12.1 DISCUSSION GUIDE 201
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
12.3 CUSTOMIZATION OPTIONS 206
12.4 RELATED REPORTS 206
12.5 AUTHOR DETAILS 207

ページTOPに戻る

Table of Contents

Summary

The CRISPR market is projected to reach USD 7.1 billion by 2028 from USD 3.4 billion in 2023, at a CAGR of 15.6% during the forecast period. The major factors driving the growth of the CRISPR market are the advancements and increasing demand gene editing technology, and rising funding and investment of government and private organizations is expected to propel the growth of the market. However, ethical and regulatory considerations are expected to restrain market growth to a certain extent.
The CRISPR market has been segmented based on product, application, end user, and region.
“By products & services, the products segment accounted for the largest share of the CRISPR market”
Based on products & services, the CRISPR market is categorized into products, and services. The products segment dominated the market in 2023, owing to rising demand for CRISPR products in gene editing technology domain. Along with this, advancements in delivery systems, increasing investment in gene editing research and the rising number of collaborations between academic institutions and pharmaceutical companies has led to a higher growth rate for products in the CRISPR market.
“By application, drug discovery & development segment accounted for the largest share in the CRISPR market”
Based on application, the CRISPR market is segmented into drug discovery and development, agriculture, and other applications. In 2023, the drug discovery & development segment accounted for a larger share of the CRISPR market. Growth in this market segment can be attributed to exceptional precision and efficiency offered by CRISPR-Cas9 in editing and manipulating genes. Along with this, growing demand for personalized medicine, and increased research and development activities in the field of CRISPR technology are contributing to its adoption in drug discovery and development.

“North America: the largest share of the CRISPR market”
North America accounted for the largest share of the CRISPR market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in gene editing research. The presence of top academic institutions, and private companies in North America with dedicated gene editing research programs and expertise has contributed to the growth of the CRISPR market.
“Asia Pacific: The fastest-growing region in the CRISPR market.”
The Asia Pacific CRISPR market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing demand of personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific CRISPR market is the region's large and rapidly increasing population.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Executives - 55%, Research Scientists- 25%, and Managers - 20%
• By Country: North America- 50%, Europe- 20%, Asia Pacific- 15%, Latin America - 10%, and Middle East Africa- 5%

Prominent Players
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Genscript Biotech Corporation (China)
• CRISPR Therapeutics AG (Switzerland)
• Editas Medicine (US)
• Intellia Therapeutics, Inc. (US)
• Beam Therapeutics Inc. (US)
• Caribou Biosciences, Inc. (US)
• Lonza Group, Ltd. (Switzerland)
• Danaher Corporation (US)
• PerkinElmer, Inc. (US)
• Hera Biolabs (US)
• OriGene Technologies, Inc. (US)
• Cellecta, Inc. (US)
• Mammoth Biosciences, Inc. (US)
• Applied StemCell (US)
• New England Biolabs Inc. (US)
• ToolGen Inc. (South Korea)
• GeneCopoeia, Inc. (US)
• Twist Bioscience Corporation (US)
• Synthego Corporation (US)
• eGenesis (US)
• Inscripta, Inc. (US)
• Precision BioSciences, Inc. (US)
Research Coverage:
This report provides a detailed picture of the CRISPR market. It aims at estimating the size and future growth potential of the market across different segments, such as the product & services (Products(CRISPR kits & enzymes, CRISPR libraries, and other products), and services (gRNA synthesis & cell line development, CRISPR screening & validation services, and other services)), application (drug discovery & development, agriculture, and other applications), and end user (pharmaceutical and biotechnology companies, academic and research institutes, and other applications) and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CRISPR market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers:
• Analysis of key drivers (growing demand for CRISPR-based gene therapies, growing advancements and adoptions of CRISPR technology, and growing investment and funding from the government for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccine and treatment of genetic diseases), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the CRISPR market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the CRISPR market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the CRISPR market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China) among others in the CRISPR market strategies. The report also helps stakeholders understand the pulse of the gene editing market and provides them information on key market drivers, restraints, challenges and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（application drug）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（application drug）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?